Bio-Techne Sales Corporation

Minneapolis, MN Part of Bio-Techne Corporation

UEI
EF7GFHEAB426
CAGE
9HQR6
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
614 McKinley Pl NE, Minneapolis, MN 55413, USA
Website
bio-techne.com
Founded
1976
Employees
1K-5K
Estimated annual revenue
$1B-$10B
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $34,273
FY2025 $146,422
FY2024 $68,047
FY2023 $136,359

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $34,273

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Bio-Techne Sales Corporation, a Minneapolis-based subsidiary of Bio-Techne Corporation, supplies specialized biological research products including assay kits, recombinant proteins, reagents, and diagnostic consumables to federal agencies as a prime contractor on full-and-open competitive procurements; the vendor holds no set-aside certifications and competes exclusively in unrestricted federal markets.

Bio-Techne Sales Corporation operates exclusively as a prime contractor (100% of recent awards) on small-dollar, firm-fixed-price purchase orders and blanket purchase agreement calls. The vendor's portfolio spans biological product manufacturing (11 awards) and in-vitro diagnostic substance manufacturing (8 awards) under top NAICS codes 326999 and 325414, with procurement categories centered on in-vitro diagnostic substances, reagents and test kits (7 awards), and drugs and biologicals (6 awards). Recent representative work includes a $34,272.85 purchase order from the NIH Clinical Center on September 9, 2026, for recombinant rat leptin protein; a $24,693.50 firm-fixed-price order from the National Institute on Aging on August 26, 2025, for human FGF-21 QUANTIKINE ELISA kits; a $39,840 BPA call from the Defense Health Agency on July 22, 2025, for generation cartridges; and an $11,033 purchase order from the National Heart, Lung, and Blood Institute on August 18, 2025, for Luminex assays to measure 28 analytes supporting lymphangioleiomyomatosis research.

Customer concentration is skewed toward defense and health-research buyers. The Department of the Army Medical Command dominates both volume and dollar share, accounting for 4 awards (19% of total) representing $4.2 million in combined potential value (93% of the vendor's $4.5 million total portfolio). The remaining 67% of awards distribute across the National Institutes of Health's Clinical Center, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute on Aging, National Heart, Lung, and Blood Institute, and the Defense Health Agency. The vendor serves 12 distinct federal agencies across all recent work.

Bio-Techne's primary vehicle position is a single-award Blanket Purchase Agreement with the Department of the Army Medical Command (MEDCOM) established September 23, 2024, with a $4.121 million ceiling running through September 22, 2029. Five task orders have been issued under this BPA, totaling $111 thousand in combined potential value, covering reagent cartridge kits, SIMPLE PLEX assay cartridges, and specialized consumables for biomedical research spanning cancer, environmental health, substance abuse, infectious disease, and translational science domains. The Defense Health Agency and NIH Clinical Center have issued supplemental calls under and outside this vehicle for generation cartridges, assay kits, and recombinant proteins.

Activity has remained consistent at six to eight awards annually from 2023 through 2025, with only one award logged in 2026 year-to-date. One award (valued at $34 thousand) faces recompete within the next twenty-four months. The vendor operates solely as a prime; no subcontract awards appear in the source record. Bio-Techne Sales Corporation is a subsidiary of Bio-Techne Corporation, a for-profit parent organization that also holds prime federal contract and grant awards.

Quick answers

Is Bio-Techne Sales Corporation registered in SAM.gov?

Yes. Bio-Techne Sales Corporation's SAM.gov registration is active through January 2, 2027.

How much has Bio-Techne Sales Corporation received in federal contracts?

Federal contracts obligated $146,422 to Bio-Techne Sales Corporation in fiscal year 2025 and $385,101 in fiscal years 2023 through 2027.

How does Bio-Techne Sales Corporation rank among federal contractors?

Bio-Techne Sales Corporation ranked #82 in PSC 6550 and #92 in NAICS 325413 in FY2025.

What is Bio-Techne Sales Corporation's most recent federal award?

Bio-Techne Sales Corporation's most recent federal contract award is Recombinant RAT leptin protein, CF (75N98026P01528), from Office of Logisitics and Acquisition Operations (NIH), on September 9, 2026.

On GovTribe

See Bio-Techne Sales Corporation's full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors